> top > docs > PubMed:24403068 > annotations

PubMed:24403068 JSONTXT

Annnotations TAB JSON ListView MergeView

CL-cell

Id Subject Object Predicate Lexical cue cl_id
T1 154-172 Cell denotes hematopoietic cell http://purl.obolibrary.org/obo/CL:0000988
T2 732-742 Cell denotes hepatocyte http://purl.obolibrary.org/obo/CL:0000182
T3 948-973 Cell denotes bone marrow stromal cells http://purl.obolibrary.org/obo/CL:0000134
T4 1139-1161 Cell denotes attachment to the cell http://purl.obolibrary.org/obo/CL:0000386

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 108-282 DRI_Background denotes Recently, it was discovered that serglycin, a hematopoietic cell proteoglycan, is the major proteoglycan expressed and constitutively secreted by multiple myeloma (MM) cells.
T2 283-396 DRI_Background denotes High levels of serglycin are present in the bone marrow aspirates of at least 30% of newly diagnosed MM patients.
T3 397-463 DRI_Background denotes However, its contribution to the pathophysiology of MM is unknown.
T4 464-547 DRI_Outcome denotes Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using
T5 564-652 DRI_Outcome denotes , dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency.
T6 653-867 DRI_Approach denotes Tumors formed from cells deficient in serglycin exhibited diminished levels of hepatocyte growth factor expression and impaired development of blood vessels, indicating that serglycin may affect tumor angiogenesis.
T7 868-989 DRI_Background denotes Furthermore, knockdown of serglycin significantly decreased MM cell adhesion to bone marrow stromal cells and collagen I.
T8 990-1241 DRI_Outcome denotes Even though serglycin proteoglycan does not have a transmembrane domain, flow cytometry showed that serglycin is present on the MM cell surface, and attachment to the cell surface is, at least in part, dependent on its chondroitin sulfate side chains.
T9 1242-1500 DRI_Approach denotes Co-precipitation of serglycin from conditioned medium of MM cells using a CD44-Fc chimera suggests that CD44 is the cell surface-binding partner for serglycin, which therefore may serve as a major ligand for CD44 at various stages during myeloma progression.
T10 1501-1680 DRI_Outcome denotes Finally, we demonstrate that serglycin mRNA expression in MM cells is up-regulated by activin, a predominant cytokine among those increased in MM patients with osteolytic lesions.
T11 1681-1854 DRI_Background denotes These studies provide direct evidence for a critical role for serglycin in MM pathogenesis and show that targeting serglycin may provide a novel therapeutic approach for MM.

GlyCosmos6-Glycan-Motif-Image

Id Subject Object Predicate Lexical cue image
T1 1209-1220 Glycan_Motif denotes chondroitin https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G43702JT

GlyCosmos6-Glycan-Motif-Structure

Id Subject Object Predicate Lexical cue
T1 1209-1220 https://glytoucan.org/Structures/Glycans/G43702JT denotes chondroitin

Glycosmos6-GlycoEpitope

Id Subject Object Predicate Lexical cue glyco_epitope_db_id
T1 1209-1220 GlycoEpitope denotes chondroitin http://www.glycoepitope.jp/epitopes/EP0081

sentences

Id Subject Object Predicate Lexical cue
T1 0-107 Sentence denotes Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.
T2 108-282 Sentence denotes Recently, it was discovered that serglycin, a hematopoietic cell proteoglycan, is the major proteoglycan expressed and constitutively secreted by multiple myeloma (MM) cells.
T3 283-396 Sentence denotes High levels of serglycin are present in the bone marrow aspirates of at least 30% of newly diagnosed MM patients.
T4 397-463 Sentence denotes However, its contribution to the pathophysiology of MM is unknown.
T5 464-652 Sentence denotes Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using lentiviral shRNA, dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency.
T6 653-867 Sentence denotes Tumors formed from cells deficient in serglycin exhibited diminished levels of hepatocyte growth factor expression and impaired development of blood vessels, indicating that serglycin may affect tumor angiogenesis.
T7 868-989 Sentence denotes Furthermore, knockdown of serglycin significantly decreased MM cell adhesion to bone marrow stromal cells and collagen I.
T8 990-1241 Sentence denotes Even though serglycin proteoglycan does not have a transmembrane domain, flow cytometry showed that serglycin is present on the MM cell surface, and attachment to the cell surface is, at least in part, dependent on its chondroitin sulfate side chains.
T9 1242-1500 Sentence denotes Co-precipitation of serglycin from conditioned medium of MM cells using a CD44-Fc chimera suggests that CD44 is the cell surface-binding partner for serglycin, which therefore may serve as a major ligand for CD44 at various stages during myeloma progression.
T10 1501-1680 Sentence denotes Finally, we demonstrate that serglycin mRNA expression in MM cells is up-regulated by activin, a predominant cytokine among those increased in MM patients with osteolytic lesions.
T11 1681-1854 Sentence denotes These studies provide direct evidence for a critical role for serglycin in MM pathogenesis and show that targeting serglycin may provide a novel therapeutic approach for MM.

Glycosmos6-MAT

Id Subject Object Predicate Lexical cue
T1 327-338 http://purl.obolibrary.org/obo/MAT_0000084 denotes bone marrow
T2 327-331 http://purl.obolibrary.org/obo/MAT_0000299 denotes bone
T3 796-809 http://purl.obolibrary.org/obo/MAT_0000393 denotes blood vessels
T4 796-801 http://purl.obolibrary.org/obo/MAT_0000083 denotes blood
T5 796-801 http://purl.obolibrary.org/obo/MAT_0000315 denotes blood
T6 948-959 http://purl.obolibrary.org/obo/MAT_0000084 denotes bone marrow
T7 948-952 http://purl.obolibrary.org/obo/MAT_0000299 denotes bone

DisGeNET

Id Subject Object Predicate Lexical cue
T0 0-22 gene:5552 denotes Serglycin proteoglycan
T1 39-55 disease:C0026764 denotes multiple myeloma
T2 141-150 gene:5552 denotes serglycin
T3 254-274 disease:C0026764 denotes multiple myeloma (MM
T4 298-307 gene:5552 denotes serglycin
T5 384-386 disease:C0026764 denotes MM
T6 483-492 gene:5552 denotes serglycin
T7 590-592 disease:C0026764 denotes MM
T8 483-492 gene:5552 denotes serglycin
T9 619-651 disease:C0085110 denotes severe combined immunodeficiency
T10 827-836 gene:5552 denotes serglycin
T11 848-866 disease:C1519670 denotes tumor angiogenesis
T12 732-756 gene:3082 denotes hepatocyte growth factor
T13 848-866 disease:C1519670 denotes tumor angiogenesis
T14 691-700 gene:5552 denotes serglycin
T15 848-866 disease:C1519670 denotes tumor angiogenesis
T16 1090-1099 gene:5552 denotes serglycin
T17 1118-1120 disease:C0026764 denotes MM
T18 1002-1024 gene:5552 denotes serglycin proteoglycan
T19 1118-1120 disease:C0026764 denotes MM
T20 1450-1454 gene:960 denotes CD44
T21 1480-1487 disease:C0026764 denotes myeloma
T22 1346-1350 gene:960 denotes CD44
T23 1480-1487 disease:C0026764 denotes myeloma
T24 1391-1400 gene:5552 denotes serglycin
T25 1480-1487 disease:C0026764 denotes myeloma
T26 1262-1271 gene:5552 denotes serglycin
T27 1299-1301 disease:C0026764 denotes MM
T28 1262-1271 gene:5552 denotes serglycin
T29 1480-1487 disease:C0026764 denotes myeloma
T30 1316-1320 gene:960 denotes CD44
T31 1480-1487 disease:C0026764 denotes myeloma
T32 1530-1539 gene:5552 denotes serglycin
T33 1559-1561 disease:C0026764 denotes MM
R1 T0 T1 associated_with Serglycin proteoglycan,multiple myeloma
R2 T2 T3 associated_with serglycin,multiple myeloma (MM
R3 T4 T5 associated_with serglycin,MM
R4 T6 T7 associated_with serglycin,MM
R5 T8 T9 associated_with serglycin,severe combined immunodeficiency
R6 T10 T11 associated_with serglycin,tumor angiogenesis
R7 T12 T13 associated_with hepatocyte growth factor,tumor angiogenesis
R8 T14 T15 associated_with serglycin,tumor angiogenesis
R9 T16 T17 associated_with serglycin,MM
R10 T18 T19 associated_with serglycin proteoglycan,MM
R11 T20 T21 associated_with CD44,myeloma
R12 T22 T23 associated_with CD44,myeloma
R13 T24 T25 associated_with serglycin,myeloma
R14 T26 T27 associated_with serglycin,MM
R15 T28 T29 associated_with serglycin,myeloma
R16 T30 T31 associated_with CD44,myeloma
R17 T32 T33 associated_with serglycin,MM

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 254-270 HP_0006775 denotes multiple myeloma
T2 339-348 HP_0002835 denotes aspirates
T3 593-598 HP_0002664 denotes tumor
T4 619-651 HP_0004430 denotes severe combined immunodeficiency
T5 626-651 HP_0005387 denotes combined immunodeficiency
T6 635-651 HP_0002721 denotes immunodeficiency
T7 653-659 HP_0002664 denotes Tumors
T8 848-853 HP_0002664 denotes tumor

Allie

Id Subject Object Predicate Lexical cue
SS1_24403068_1_0 254-270 expanded denotes multiple myeloma
SS2_24403068_1_0 272-274 abbr denotes MM
AE1_24403068_1_0 SS1_24403068_1_0 SS2_24403068_1_0 abbreviatedTo multiple myeloma,MM

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
24403068-0#0#22#gene5552 0-22 gene5552 denotes Serglycin proteoglycan
24403068-0#39#55#diseaseC0026764 39-55 diseaseC0026764 denotes multiple myeloma
24403068-4#19#28#gene5552 483-492 gene5552 denotes serglycin
24403068-4#155#187#diseaseC0085110 619-651 diseaseC0085110 denotes severe combined immunodeficiency
24403068-5#38#47#gene5552 691-700 gene5552 denotes serglycin
24403068-5#79#103#gene3082 732-756 gene3082 denotes hepatocyte growth factor
24403068-5#174#183#gene5552 827-836 gene5552 denotes serglycin
24403068-5#195#213#diseaseC1519670 848-866 diseaseC1519670 denotes tumor angiogenesis
24403068-8#74#78#gene960 1316-1320 gene960 denotes CD44
24403068-8#104#108#gene960 1346-1350 gene960 denotes CD44
24403068-8#208#212#gene960 1450-1454 gene960 denotes CD44
24403068-8#238#245#diseaseC0026764 1480-1487 diseaseC0026764 denotes myeloma
0#22#gene555239#55#diseaseC0026764 24403068-0#0#22#gene5552 24403068-0#39#55#diseaseC0026764 associated_with Serglycin proteoglycan,multiple myeloma
19#28#gene5552155#187#diseaseC0085110 24403068-4#19#28#gene5552 24403068-4#155#187#diseaseC0085110 associated_with serglycin,severe combined immunodeficiency
38#47#gene5552195#213#diseaseC1519670 24403068-5#38#47#gene5552 24403068-5#195#213#diseaseC1519670 associated_with serglycin,tumor angiogenesis
79#103#gene3082195#213#diseaseC1519670 24403068-5#79#103#gene3082 24403068-5#195#213#diseaseC1519670 associated_with hepatocyte growth factor,tumor angiogenesis
174#183#gene5552195#213#diseaseC1519670 24403068-5#174#183#gene5552 24403068-5#195#213#diseaseC1519670 associated_with serglycin,tumor angiogenesis
74#78#gene960238#245#diseaseC0026764 24403068-8#74#78#gene960 24403068-8#238#245#diseaseC0026764 associated_with CD44,myeloma
104#108#gene960238#245#diseaseC0026764 24403068-8#104#108#gene960 24403068-8#238#245#diseaseC0026764 associated_with CD44,myeloma
208#212#gene960238#245#diseaseC0026764 24403068-8#208#212#gene960 24403068-8#238#245#diseaseC0026764 associated_with CD44,myeloma

mondo_disease

Id Subject Object Predicate Lexical cue mondo_id
T1 39-55 Disease denotes multiple myeloma http://purl.obolibrary.org/obo/MONDO_0009693
T2 254-270 Disease denotes multiple myeloma http://purl.obolibrary.org/obo/MONDO_0009693
T3 272-274 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T4 384-386 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T5 449-451 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T6 590-592 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T7 593-598 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T8 619-651 Disease denotes severe combined immunodeficiency http://purl.obolibrary.org/obo/MONDO_0015974
T9 653-659 Disease denotes Tumors http://purl.obolibrary.org/obo/MONDO_0005070
T10 848-853 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T11 928-930 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T12 1118-1120 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T13 1299-1301 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T14 1480-1487 Disease denotes myeloma http://purl.obolibrary.org/obo/MONDO_0005170|http://purl.obolibrary.org/obo/MONDO_0009693
T16 1559-1561 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T17 1644-1646 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T18 1661-1679 Disease denotes osteolytic lesions http://purl.obolibrary.org/obo/MONDO_0043731
T19 1756-1758 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T20 1851-1853 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693

Glycan-GlyCosmos

Id Subject Object Predicate Lexical cue image
T1 1209-1220 Glycan denotes chondroitin https://api.glycosmos.org/wurcs2image/latest/png/binary/G43702JT

GlyCosmos-GlycoEpitope

Id Subject Object Predicate Lexical cue glycoepitope_id
T1 1209-1220 http://purl.jp/bio/12/glyco/glycan#Glycan_epitope denotes chondroitin http://www.glycoepitope.jp/epitopes/EP0081

GlyCosmos15-HP

Id Subject Object Predicate Lexical cue hp_id
T1 39-55 Phenotype denotes multiple myeloma HP:0006775
T2 254-270 Phenotype denotes multiple myeloma HP:0006775
T3 272-274 Phenotype denotes MM HP:0006775
T4 384-386 Phenotype denotes MM HP:0006775
T5 449-451 Phenotype denotes MM HP:0006775
T6 590-592 Phenotype denotes MM HP:0006775
T7 593-598 Phenotype denotes tumor HP:0002664
T8 619-651 Phenotype denotes severe combined immunodeficiency HP:0004430
T9 848-853 Phenotype denotes tumor HP:0002664
T10 928-930 Phenotype denotes MM HP:0006775
T11 1118-1120 Phenotype denotes MM HP:0006775
T12 1299-1301 Phenotype denotes MM HP:0006775
T13 1559-1561 Phenotype denotes MM HP:0006775
T14 1644-1646 Phenotype denotes MM HP:0006775
T15 1756-1758 Phenotype denotes MM HP:0006775
T16 1851-1853 Phenotype denotes MM HP:0006775

GlyCosmos15-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 39-55 Disease denotes multiple myeloma http://purl.obolibrary.org/obo/MONDO_0009693
T2 254-270 Disease denotes multiple myeloma http://purl.obolibrary.org/obo/MONDO_0009693
T3 272-274 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T4 384-386 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T5 449-451 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T6 590-592 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T7 593-598 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T8 619-651 Disease denotes severe combined immunodeficiency http://purl.obolibrary.org/obo/MONDO_0015974
T9 653-659 Disease denotes Tumors http://purl.obolibrary.org/obo/MONDO_0005070
T10 848-853 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T11 928-930 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T12 1118-1120 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T13 1299-1301 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T14 1480-1487 Disease denotes myeloma http://purl.obolibrary.org/obo/MONDO_0005170|http://purl.obolibrary.org/obo/MONDO_0009693
T16 1559-1561 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T17 1644-1646 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T18 1661-1679 Disease denotes osteolytic lesions http://purl.obolibrary.org/obo/MONDO_0043731
T19 1756-1758 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693
T20 1851-1853 Disease denotes MM http://purl.obolibrary.org/obo/MONDO_0009693

GlyCosmos15-NCBITAXON

Id Subject Object Predicate Lexical cue db_id
T1 609-613 OrganismTaxon denotes mice 10088

GlyCosmos15-CL

Id Subject Object Predicate Lexical cue cl_id
T1 154-172 Cell denotes hematopoietic cell http://purl.obolibrary.org/obo/CL:0000988
T2 732-742 Cell denotes hepatocyte http://purl.obolibrary.org/obo/CL:0000182
T3 948-973 Cell denotes bone marrow stromal cells http://purl.obolibrary.org/obo/CL:0000134
T4 1139-1161 Cell denotes attachment to the cell http://purl.obolibrary.org/obo/CL:0000386

GlyCosmos15-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 154-172 Body_part denotes hematopoietic cell http://purl.obolibrary.org/obo/CL_0000988
T2 327-338 Body_part denotes bone marrow http://purl.obolibrary.org/obo/UBERON_0002371
T3 732-742 Body_part denotes hepatocyte http://purl.obolibrary.org/obo/CL_0000182
T4 796-809 Body_part denotes blood vessels http://purl.obolibrary.org/obo/UBERON_0004537
T5 948-973 Body_part denotes bone marrow stromal cells http://purl.obolibrary.org/obo/CL_0000134
T6 1041-1054 Body_part denotes transmembrane http://purl.obolibrary.org/obo/GO_0016020
T7 1139-1161 Body_part denotes attachment to the cell http://purl.obolibrary.org/obo/CL_0000386

GlyCosmos15-MAT

Id Subject Object Predicate Lexical cue mat_id
T1 327-338 Body_part denotes bone marrow http://purl.obolibrary.org/obo/MAT_0000084
T2 796-809 Body_part denotes blood vessels http://purl.obolibrary.org/obo/MAT_0000393
T3 948-959 Body_part denotes bone marrow http://purl.obolibrary.org/obo/MAT_0000084

sentences

Id Subject Object Predicate Lexical cue
T1 0-107 Sentence denotes Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.
T2 108-282 Sentence denotes Recently, it was discovered that serglycin, a hematopoietic cell proteoglycan, is the major proteoglycan expressed and constitutively secreted by multiple myeloma (MM) cells.
T3 283-396 Sentence denotes High levels of serglycin are present in the bone marrow aspirates of at least 30% of newly diagnosed MM patients.
T4 397-463 Sentence denotes However, its contribution to the pathophysiology of MM is unknown.
T5 464-652 Sentence denotes Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using lentiviral shRNA, dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency.
T6 653-867 Sentence denotes Tumors formed from cells deficient in serglycin exhibited diminished levels of hepatocyte growth factor expression and impaired development of blood vessels, indicating that serglycin may affect tumor angiogenesis.
T7 868-989 Sentence denotes Furthermore, knockdown of serglycin significantly decreased MM cell adhesion to bone marrow stromal cells and collagen I.
T8 990-1241 Sentence denotes Even though serglycin proteoglycan does not have a transmembrane domain, flow cytometry showed that serglycin is present on the MM cell surface, and attachment to the cell surface is, at least in part, dependent on its chondroitin sulfate side chains.
T9 1242-1500 Sentence denotes Co-precipitation of serglycin from conditioned medium of MM cells using a CD44-Fc chimera suggests that CD44 is the cell surface-binding partner for serglycin, which therefore may serve as a major ligand for CD44 at various stages during myeloma progression.
T10 1501-1680 Sentence denotes Finally, we demonstrate that serglycin mRNA expression in MM cells is up-regulated by activin, a predominant cytokine among those increased in MM patients with osteolytic lesions.
T11 1681-1854 Sentence denotes These studies provide direct evidence for a critical role for serglycin in MM pathogenesis and show that targeting serglycin may provide a novel therapeutic approach for MM.

GlyCosmos15-Sentences

Id Subject Object Predicate Lexical cue
T1 0-107 Sentence denotes Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.
T2 108-282 Sentence denotes Recently, it was discovered that serglycin, a hematopoietic cell proteoglycan, is the major proteoglycan expressed and constitutively secreted by multiple myeloma (MM) cells.
T3 283-396 Sentence denotes High levels of serglycin are present in the bone marrow aspirates of at least 30% of newly diagnosed MM patients.
T4 397-463 Sentence denotes However, its contribution to the pathophysiology of MM is unknown.
T5 464-652 Sentence denotes Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using lentiviral shRNA, dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency.
T6 653-867 Sentence denotes Tumors formed from cells deficient in serglycin exhibited diminished levels of hepatocyte growth factor expression and impaired development of blood vessels, indicating that serglycin may affect tumor angiogenesis.
T7 868-1241 Sentence denotes Furthermore, knockdown of serglycin significantly decreased MM cell adhesion to bone marrow stromal cells and collagen I. Even though serglycin proteoglycan does not have a transmembrane domain, flow cytometry showed that serglycin is present on the MM cell surface, and attachment to the cell surface is, at least in part, dependent on its chondroitin sulfate side chains.
T8 1242-1500 Sentence denotes Co-precipitation of serglycin from conditioned medium of MM cells using a CD44-Fc chimera suggests that CD44 is the cell surface-binding partner for serglycin, which therefore may serve as a major ligand for CD44 at various stages during myeloma progression.
T9 1501-1680 Sentence denotes Finally, we demonstrate that serglycin mRNA expression in MM cells is up-regulated by activin, a predominant cytokine among those increased in MM patients with osteolytic lesions.
T10 1681-1854 Sentence denotes These studies provide direct evidence for a critical role for serglycin in MM pathogenesis and show that targeting serglycin may provide a novel therapeutic approach for MM.

GlyCosmos15-Glycan

Id Subject Object Predicate Lexical cue image
T1 1209-1220 Glycan denotes chondroitin https://api.glycosmos.org/wurcs2image/latest/png/binary/G43702JT

GlyCosmos15-GlycoEpitope

Id Subject Object Predicate Lexical cue glycoepitope_id
T1 1209-1220 http://purl.jp/bio/12/glyco/glycan#Glycan_epitope denotes chondroitin http://www.glycoepitope.jp/epitopes/EP0081

NCBITAXON

Id Subject Object Predicate Lexical cue db_id
T1 609-613 OrganismTaxon denotes mice 10088

Anatomy-MAT

Id Subject Object Predicate Lexical cue mat_id
T1 327-338 Body_part denotes bone marrow http://purl.obolibrary.org/obo/MAT_0000084
T2 796-809 Body_part denotes blood vessels http://purl.obolibrary.org/obo/MAT_0000393
T3 948-959 Body_part denotes bone marrow http://purl.obolibrary.org/obo/MAT_0000084

Anatomy-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 154-172 Body_part denotes hematopoietic cell http://purl.obolibrary.org/obo/CL_0000988
T2 327-338 Body_part denotes bone marrow http://purl.obolibrary.org/obo/UBERON_0002371
T3 732-742 Body_part denotes hepatocyte http://purl.obolibrary.org/obo/CL_0000182
T4 796-809 Body_part denotes blood vessels http://purl.obolibrary.org/obo/UBERON_0004537
T5 948-973 Body_part denotes bone marrow stromal cells http://purl.obolibrary.org/obo/CL_0000134
T6 1041-1054 Body_part denotes transmembrane http://purl.obolibrary.org/obo/GO_0016020
T7 1139-1161 Body_part denotes attachment to the cell http://purl.obolibrary.org/obo/CL_0000386

HP-phenotype

Id Subject Object Predicate Lexical cue hp_id
T1 39-55 Phenotype denotes multiple myeloma HP:0006775
T2 254-270 Phenotype denotes multiple myeloma HP:0006775
T3 272-274 Phenotype denotes MM HP:0006775
T4 384-386 Phenotype denotes MM HP:0006775
T5 449-451 Phenotype denotes MM HP:0006775
T6 590-592 Phenotype denotes MM HP:0006775
T7 593-598 Phenotype denotes tumor HP:0002664
T8 619-651 Phenotype denotes severe combined immunodeficiency HP:0004430
T9 848-853 Phenotype denotes tumor HP:0002664
T10 928-930 Phenotype denotes MM HP:0006775
T11 1118-1120 Phenotype denotes MM HP:0006775
T12 1299-1301 Phenotype denotes MM HP:0006775
T13 1559-1561 Phenotype denotes MM HP:0006775
T14 1644-1646 Phenotype denotes MM HP:0006775
T15 1756-1758 Phenotype denotes MM HP:0006775
T16 1851-1853 Phenotype denotes MM HP:0006775